Skip to content

Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia

Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00972231
Enrollment
93
Registered
2009-09-04
Start date
2009-01-31
Completion date
2010-12-31
Last updated
2015-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease, Thalassemia

Keywords

Thalassemia Major, Thalassemia Intermedia, Sickle Cell Anemia, Sickle Cell Thalassemia, Iron Overload, Growth Velocity

Brief summary

Iron overload impaired growth in Thalassemia patients due to iron deposition in the endocrine glands, including the hypophysis and gonads. The issue of iron overload in Sickle Cell Anemia is recently studied more extensively and preliminary studies shows that endocrine damage is rarer in those patients. Growth velocity was not systematically studied in patients with Iron Overload, even in thalassemia patients in spite several studies that assess the endocrine function in those patients. In Sickle Cell Patients this issue was not studied. The purpose of this study is to assess the growth velocity in a cohort of Thalassemia Major and Intermedia patients and compare the results to another group of Sickle Cell patients, including Sickle cell thalassemia.

Detailed description

Growth velocity, endocrine function and iron overload status will be studied in the patients that are in follow up at the Pediatric Hematology Unit, at the Ha'Emek Medical Center. Patients who were lost from follow up or insufficient data about growth in the past will not included in the study.

Interventions

OTHERMedical Chart Summary

Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* All patients in follow up with available medical charts.

Exclusion criteria

* Patients lost from follow up or without enough data to calculate growth velocity or clinical and laboratory endocrine assessment or missing data about iron status.

Design outcomes

Primary

MeasureTime frameDescription
Iron Overload and Growth Velocity in Thalassemia and Sickle Cell AnemiaOne yearAnalysis of Growth Velocity in Thalassemia and Sickle Cell Anemia and correlation with Iron Overload

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026